If a man’s PSA level is very low (under 1) at age 60, he’s extremely unlikely to ever die from prostate cancer — so he probably doesn’t need to be screened anymore.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether PSA <1 ng/mL at age 60 reliably identifies men with negligible risk of prostate cancer mortality across diverse populations.
A systematic review and meta-analysis of all prospective studies measuring PSA at age 60 and tracking prostate cancer mortality over 20+ years, stratifying by PSA thresholds (<1, 1–2, >2 ng/mL).
Whether men with PSA <1 ng/mL at age 60 have a near-zero risk of prostate cancer death over 15–20 years.
A prospective cohort of 20,000 men aged 60 with PSA <1 ng/mL, followed for 20 years with annual PSA and cancer/mortality data collection, comparing outcomes to those with higher PSA.
Whether men who died from prostate cancer had significantly higher PSA levels at age 60 than matched controls who survived.
A case-control study of 1,000 men who died from prostate cancer vs. 1,000 age-matched survivors, with archived serum samples from age 60 to compare PSA levels.
Whether withholding PSA screening in men with PSA <1 ng/mL at age 60 is safe compared to routine screening.
A multicenter RCT of 10,000 men aged 60 with PSA <1 ng/mL randomized to screening every 2 years vs. no screening, with prostate cancer mortality as primary endpoint over 15 years.
Expert consensus on whether PSA <1 ng/mL at age 60 justifies discontinuing screening.
A consensus panel of 25 oncologists and urologists evaluating evidence for screening cessation in men with PSA <1 ng/mL at age 60.